Partnership comprises two parts:
Strategic research agreement (SRA) where Sensyne will receive de-identified Sentara patient data for analysis in AI-driven life sciences research
Collaboration agreement to co-design, validate, and deploy new clinical algorithms in the areas of Chronic Kidney Disease (CKD) and Congestive Heart Failure (CHF)
Sensyne Health plc (LSE: SENS) ("Sensyne" or the "Company" or the "Group"), the ethical clinical AI company, today announces that it has signed a Strategic Research Agreement (SRA) and a Collaboration Agreement with Sentara Healthcare ("Sentara"), a leading healthcare system serving patients in Virginia and northeastern North Carolina through 12 acute hospitals with more than 300 sites of care.
Sentara will join 11 UK NHS Trusts and U.S. Health Systems who are partners and shareholders in Sensyne Health. The new agreement is Sensyne's third U.S. partnership since launching in the U.S. in December 2020. The addition of Sentara's 3.6 million patients brings Sensyne's combined total of de-identified patient data for medical research to 21.7 million patients.
The partnership combines both life sciences research and healthcare algorithm development that will deliver value back to Sentara and its patients. The agreement will enable the ethical application of clinical AI research by Sensyne through analyzing Sentara's patient dataset to improve patient care and accelerate medical research. As part of a collaboration agreement, Sentara also becomes the first of several U.S. health systems that will partner with Sensyne to implement new clinical algorithms to support patients with CKD and CHF.
Jordan Asher, Executive Vice President and Chief Physician Executive of Sentara Healthcare, said:
"The combination of data and clinical expertise has the power to drive innovation, further advance research and enhance our ability to deliver complex and high-specialized clinical care to the communities we serve. The Sensyne partnership has the potential to help our organization continue our mission of improving health every day in critical areas of healthcare, including health equity."
Tim Skeen, Chief Information Officer of Sentara Healthcare, said:
"One of our top priorities at Sentara is protecting our patients' healthcare information, and via our partnership with Sensyne and its ethically designed AI, we are able to do just that. Sensyne is aligned with our vision of advancing clinical research, especially in critical medical areas like CKD and CHF. It is exciting to be able to leverage Sensyne's ground-breaking technologies and unique algorithms to truly move the needle on treatment development, ultimately improving our patients' outcomes."
Derek Baird, President, North America of Sensyne Health, said:
"This Sentara relationship expands our model in the U.S, where we want to be working with our partners not only in using data for life science research, but also to deliver clinical insights back into the health system itself. This clinical co-design work is a really important aspect of our model. We expect the work we are doing with Sentara on CKD and CHF will yield powerful algorithms to manage these disease areas."
Consistent with Sensyne's approach in all its health systems' relationships, all research will be undertaken to the highest standards of information governance and data security and in accordance with The Health Insurance Portability and Accountability Act (HIPAA), the U.S. legislation that protects sensitive patient information. All data supplied to Sensyne for research will be de-identified by Sentara and will remain in the U.S., and the provision of the data will operate under an agreed set of data processing procedures.
Notes to editors:
About Sensyne Health: www.sensynehealth.com
Sensyne Health plc (LSE: SENS) is a clinical artificial intelligence company operating a unique business model a for-profit plc making a positive social impact, sharing the financial returns it makes with health systems. The company applies clinical AI in the healthcare and life science industries. In healthcare, Sensyne delivers remote patient monitoring and real-time decision-making systems for healthcare organizations and their patients. In life sciences, Sensyne analyses large complex anonymized data sets to help life sciences companies accelerate the development of new medicines.
About Sentara: www.sentara.com
Sentara Healthcare celebrates more than 130 years in pursuit of its mission "we improve health every day." Named to IBM Watson Health's "Top 15 Health Systems" in 2018 and 2021, Sentara is an integrated, not-for-profit system of 12 hospitals in Virginia and Northeastern North Carolina, including a Level I trauma center, the Sentara Heart Hospital and the Sentara Healthcare Cardiovascular Research Institute, the Sentara Brock Cancer Center and the accredited Sentara Cancer Network, two orthopedic hospitals, and the Sentara Neurosciences Institute. The Sentara family also includes four medical groups, Nightingale Regional Air Ambulance and ground medical transport, home care and hospice, ambulatory outpatient campuses, advanced imaging and diagnostic centers, a clinically integrated network, the Sentara College of Health Sciences and the Optima Health Plan and Virginia Premier Health Plan serving 858,000 members in Virginia, North Carolina and Ohio. With nearly 30,000 employees and ranked one of Forbes "America's Best Employers" in 2018, Sentara is strategically focused on clinical quality and safety, innovation and creating an extraordinary health care experience for our patients and members.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210819005147/en/
Contacts:
Ashley Owen
Aria Marketing for Sensyne Health
aowen@ariamarketing.com
(978) 257-9000
